Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease
J Andrew Woods,1 James S Wheeler,1 Christopher K Finch,2 Nathan A Pinner3
1School of Pharmacy, Wingate University, Wingate, NC, USA; 2Department of Pharmacy, Methodist University Hospital, Memphis, TN, USA; 3Harrison School of Pharmacy, Auburn University, Auburn, AL, USA
Background: Chronic obstructive pulmonary disease (COPD) is a chronic and progressive disease that affects an estimated 10% of the world's population over the age of 40 years. Worldwide, COPD ranks in the top ten for causes of disability and death. Given the significant impact of this disease, it is important to note that acute exacerbations of COPD (AECOPD) are by far the most costly and devastating aspect of disease management. Systemic steroids have long been a standard for the treatment of AECOPD; however, the optimal strategy for dosing and administration of these medications continues to be debated.
Objective: To review the use of corticosteroids in the treatment of acute exacerbations of COPD.
Materials and methods: Literature was identified through PubMed Medline (1950–February 2014) and Embase (1950–February 2014) utilizing the search terms corticosteroids, COPD, chronic bronchitis, emphysema, and exacerbation. All reference citations from identified publications were reviewed for possible inclusion. All identified randomized, placebo-controlled trials, meta-analyses, and systematic reviews evaluating the efficacy of systemic corticosteroids in the treatment of AECOPD were reviewed and summarized.
Results: The administration of corticosteroids in the treatment of AECOPD was assessed. In comparison to placebo, systemic corticosteroids improve airflow, decrease the rate of treatment failure and risk of relapse, and may improve symptoms and decrease the length of hospital stay. Therefore, corticosteroids are recommended by all major guidelines in the treatment of AECOPD. Existing literature suggests that low-dose oral corticosteroids are as efficacious as high-dose, intravenous corticosteroid regimens, while minimizing adverse effects. Recent data suggest that shorter durations of corticosteroid therapy are as efficacious as the traditional treatment durations currently recommended by guidelines.
Conclusion: Systemic corticosteroids are efficacious in the treatment of AECOPD and considered a standard of care for patients experiencing an AECOPD. Therefore, systemic corticosteroids should be administered to all patients experiencing AECOPD severe enough to seek emergent medical care. The lowest effective dose and shortest duration of therapy should be considered.
Keywords: chronic obstructive pulmonary disease, exacerbation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Readers of this article also read:
CdTe quantum dots induce activation of human platelets: implications for nanoparticle hemocompatibility
Samuel SP, Santos-Martinez MJ, Medina C, Jain N, Radomski MW, Prina-Mello A, Volkov Y
Published Date: 2 April 2015
Continuing to Confront COPD International Surveys: comparison of patient and physician perceptions about COPD risk and management
Menezes AM, Landis SH, Han MK, Muellerova H, Aisanov Z, van der Molen T, Oh YM, Ichinose M, Mannino DM, Davis KJ
Published Date: 20 January 2015
Brill SE, Wedzicha JA
Published Date: 7 November 2014
Pini L, Pinelli V, Modina D, Bezzi M, Tiberio L, Tantucci C
Published Date: 1 September 2014
Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease
Brockwell C, Ampikaipakan S, Sexton DW, Price D, Freeman D, Thomas M, Ali M, Wilson AM
Published Date: 9 July 2014
Increased serum levels of lipocalin-1 and -2 in patients with stable chronic obstructive pulmonary disease
Wang XR, Li YP, Gao S, Xia W, Gao K, Kong QH, Qi H, Wu L, Zhang J, Qu JM, Bai CX
Published Date: 27 May 2014
Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis
Oba Y, Lone NA
Published Date: 12 May 2014
Caramori G, Adcock IM, Di Stefano A, Chung KF
Published Date: 28 April 2014
Osadnik CR, McDonald CF, Holland AE
Published Date: 25 March 2014
Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences
Ohno T, Wada S, Hanada S, Sawaguchi H, Muraki M, Tohda Y
Published Date: 21 January 2014